ASX
$0.06—
Resonance Health Limited is a healthcare technology and services company specializing in the development and commercialization of software-as-medical-device (SaMD) solutions for radiological image analysis. The company creates advanced, non-invasive MRI-based tools such as FerriScan and HepaFatScan, which enable the quantitative assessment of liver iron and fat concentrations, supporting clinical management of diseases like thalassemia and fatty liver. Its AI-driven platforms, including FerriSmart and HepaFatSmart, deliver automated, real-time multi-metric measurements, while LiverSmart consolidates these into comprehensive reports. Resonance Health also offers CardiacT2 for heart iron assessment and provides MRI phantoms for quality control. Beyond clinical applications, the company operates as an imaging contract research organization, supporting pharmaceutical and therapeutic companies in clinical trials with imaging charter development, data management, and compliance services. Headquartered in Burswood, Australia, Resonance Health serves clinicians, researchers, and industry partners across more than 50 countries, maintaining regulatory clearances and a reputation for scientific rigor in medical imaging innovation.